Atopic eczema is a chronic inflammatory skin disorder with a relapsing and remitting course. For many decades,topical corticosteroids have been the mainstay therapy for atopic dermatitis. After the introduction of calcineurin inhibitors as a corticosteroid-free alternative, there were high expectations. After the black box warning from the FDA regarding the potential theoretical risk for developing neoplasia under treatment with calcineurin inhibitors, patients and physicians became uncertain about its safety, regardless of the fact that current scientific data do not support increased concern for risk of malignancy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Atopic dermatitis (AD) is a prevalent condition that has been associated with stress, but epidemiologic data on the impact of both common and severe childhood stressors are limited. Our objective was to evaluate the impact of stressful life events throughout early childhood on AD activity and severity. We conducted a longitudinal cohort study of 13,972 children ages 1 to 8.
View Article and Find Full Text PDFNLRX1 deficiency exacerbates skin inflammation in atopic dermatitis by disrupting mitophagy.
Clin Immunol
January 2025
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China. Electronic address:
NLRX1 is an important regulator of inflammatory signaling in innate immune cells. Recent studies indicate NLRX1 activation may be a novel mechanism for inflammatory diseases, however, it has not been explored in atopic dermatitis (AD). Our study aims to investigate the potential role of NLRX1 in the pathogenesis of AD.
View Article and Find Full Text PDFReporting of concomitant and rescue topical therapies in atopic dermatitis randomised controlled trials evaluating a systemic treatment: a scoping review.
Br J Dermatol
January 2025
Centre of Evidence Based Dermatology, School of Medicine, Faculty of Medicine & Health Sciences, University of Nottingham, UK.
Background: Randomised controlled trials (RCTs) evaluating new systemic treatments for atopic dermatitis (AD) have increased dramatically over the last decade. These trials often incorporate topical therapies either as permitted concomitant or rescue treatments. Differential use of these topicals post-randomisation introduces potential bias as they may nullify or exaggerate treatment responses.
View Article and Find Full Text PDFTrends in Dupilumab-Related Payments to Physicians Across Five Specialties.
Am J Rhinol Allergy
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Background: Dupilumab was first approved by the United States Food and Drug Administration in 2017 for atopic dermatitis and has since been approved for many other indications. The use of dupilumab has grown, but industry payments to physicians have yet to be explored.
Objective: The study objective is to characterize the change in payments by pharmaceutical companies to physicians for dupilumab-related promotional activities.
Orismilast for moderate-to-severe atopic dermatitis: the potential therapeutic value of a new oral pharmacological alternative.
Br J Dermatol
January 2025
Laboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra, Portugal, Coimbra, Portugal.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!